S&P 500   3,140.02 (+0.13%)
DOW   27,929.53 (+0.07%)
QQQ   204.65 (+0.28%)
AAPL   269.17 (+0.84%)
FB   200.51 (-0.41%)
MSFT   151.66 (+0.20%)
GOOGL   1,345.00 (+0.15%)
AMZN   1,750.52 (+0.06%)
CGC   20.43 (-4.04%)
NVDA   214.90 (+1.29%)
BABA   202.30 (+1.79%)
TSLA   347.25 (+2.27%)
AMD   39.34 (+1.05%)
NFLX   297.17 (-1.76%)
BAC   33.50 (-0.06%)
GILD   66.83 (-0.15%)
DIS   146.33 (+0.08%)
S&P 500   3,140.02 (+0.13%)
DOW   27,929.53 (+0.07%)
QQQ   204.65 (+0.28%)
AAPL   269.17 (+0.84%)
FB   200.51 (-0.41%)
MSFT   151.66 (+0.20%)
GOOGL   1,345.00 (+0.15%)
AMZN   1,750.52 (+0.06%)
CGC   20.43 (-4.04%)
NVDA   214.90 (+1.29%)
BABA   202.30 (+1.79%)
TSLA   347.25 (+2.27%)
AMD   39.34 (+1.05%)
NFLX   297.17 (-1.76%)
BAC   33.50 (-0.06%)
GILD   66.83 (-0.15%)
DIS   146.33 (+0.08%)
S&P 500   3,140.02 (+0.13%)
DOW   27,929.53 (+0.07%)
QQQ   204.65 (+0.28%)
AAPL   269.17 (+0.84%)
FB   200.51 (-0.41%)
MSFT   151.66 (+0.20%)
GOOGL   1,345.00 (+0.15%)
AMZN   1,750.52 (+0.06%)
CGC   20.43 (-4.04%)
NVDA   214.90 (+1.29%)
BABA   202.30 (+1.79%)
TSLA   347.25 (+2.27%)
AMD   39.34 (+1.05%)
NFLX   297.17 (-1.76%)
BAC   33.50 (-0.06%)
GILD   66.83 (-0.15%)
DIS   146.33 (+0.08%)
S&P 500   3,140.02 (+0.13%)
DOW   27,929.53 (+0.07%)
QQQ   204.65 (+0.28%)
AAPL   269.17 (+0.84%)
FB   200.51 (-0.41%)
MSFT   151.66 (+0.20%)
GOOGL   1,345.00 (+0.15%)
AMZN   1,750.52 (+0.06%)
CGC   20.43 (-4.04%)
NVDA   214.90 (+1.29%)
BABA   202.30 (+1.79%)
TSLA   347.25 (+2.27%)
AMD   39.34 (+1.05%)
NFLX   297.17 (-1.76%)
BAC   33.50 (-0.06%)
GILD   66.83 (-0.15%)
DIS   146.33 (+0.08%)
Log in

NASDAQ:AVNR - Avanir Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
AVANIR Pharmaceuticals, Inc (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:AVNR
CUSIP05348P40
Phone+1-949-3896700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive AVNR News and Ratings via Email

Sign-up to receive the latest news and ratings for AVNR and its competitors with MarketBeat's FREE daily newsletter.


Avanir Pharmaceuticals (NASDAQ:AVNR) Frequently Asked Questions

What is Avanir Pharmaceuticals' stock symbol?

Avanir Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVNR."

Has Avanir Pharmaceuticals been receiving favorable news coverage?

Headlines about AVNR stock have trended negative this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avanir Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news headlines about the healthcare company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Avanir Pharmaceuticals.

Who are some of Avanir Pharmaceuticals' key competitors?

What other stocks do shareholders of Avanir Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanir Pharmaceuticals investors own include Tellurian (TELL), Avid Bioservices (CDMO), Netflix (NFLX), Prana Biotechnology (PRAN), Nokia Oyj (NOK), GT Advanced Technologies (GTATQ), Ariad Pharmaceuticals (Aria), Groupon (GRPN), Intel (INTC) and Arena Pharmaceuticals (ARNA).

What is Avanir Pharmaceuticals' official website?

The official website for Avanir Pharmaceuticals is http://www.avanir.com/.

How can I contact Avanir Pharmaceuticals?

Avanir Pharmaceuticals' mailing address is 20 Enterprise Ste 200, ALISO VIEJO, CA 92656-7104, United States. The healthcare company can be reached via phone at +1-949-3896700.


MarketBeat Community Rating for Avanir Pharmaceuticals (NASDAQ AVNR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Avanir Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVNR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVNR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel